921224-62-6

Basic information

• Product Name: tert-butyl-6-methoxy-7-nitro-3,4-dihydroisoquinoline-2(1H)-carboxylate
• CAS NO: 921224-62-6
• Molecular Weight: 308.334
• Mol File: 921224-62-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: tert-butyl-6-methoxy-7-nitro-3,4-dihydroisoquinoline-2(1H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl-6-methoxy-7-nitro-3,4-dihydroisoquinoline-2(1H)-carboxylate(921224-62-6)
• EPA Substance Registry System: tert-butyl-6-methoxy-7-nitro-3,4-dihydroisoquinoline-2(1H)-carboxylate(921224-62-6)

Safety Data

• Hazardous Substances Data: 921224-62-6(Hazardous Substances Data)

Upstream product

• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 
• 1116230-99-9 6-methoxy-7-nitro-3,4-dihydroisoquinoline-1(2H)-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 860436-57-3 tert-butyl 6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 
• 22246-12-4 6-methoxy-1,2,3,4-tetrahydro-1-oxoisoquinoline 
• 42923-77-3 6-methoxy-1,2,3,4-tetrahydro-isoquinoline 

Relevant articles and documents

INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

Pyrimidine derivatives Anaplastic lymphoma kinase inhibitors

The invention belongs to the field of a medical technology and specifically relates to a pyrimidine derivative type anaplastic lymphoma kinase inhibitor as shown in the general formula (I) or its stereisomer, or its pharmaceutically acceptable salt, ester or solvate, wherein R1, R2, R3, R4, R5 and A ring are as defined in the specification. The invention also relates to a preparation method of the compounds, a pharmaceutic preparation and a pharmaceutical composition containing the compounds and an application of the compound or its stereisomer, or its pharmaceutically acceptable salt, ester or solvate in the preparation of medicines for treating and/or preventing diseases related to anaplastic lymphoma kinase-mediated cancer.

BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES

Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X1~X5, R1~R3, A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided.